Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Sep 27;8(1):67.
doi: 10.1186/1465-9921-8-67.

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Ian Pavord  1 , Ashley Woodcock, Debbie Parker, Leanne Rice; SOLTA study group
Affiliations
Randomized Controlled Trial

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Ian Pavord et al. Respir Res. .

Abstract

Background: Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation. In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics.

Methods: Sixty-six subjects were randomised to SFC or FP/M for 12 weeks. The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function.

Results: Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils. Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M. FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94).

Conclusion: Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC. STUDY NUMBER: SAM40030 (SOLTA).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of subjects through the study. FP, fluticasone propionate; n, number
Figure 2
Figure 2
Eosinophil count in induced sputum before and after treatment. The box is determined by the first and third quartile and the whiskers are determined by the maximum and minimum. The horizontal line represents the median value. SFC, salmeterol plus fluticasone propionate; FP/M, fluticasone propionate plus montelukast
Figure 3
Figure 3
Neutrophil count in induced sputum before and after treatment. The box is determined by the first and third quartile and the whiskers are determined by the maximum and minimum. The horizontal line represents the median value. SFC, salmeterol plus fluticasone propionate; FP/M, fluticasone propionate plus montelukast.
See this image and copyright information in PMC

References

    1. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med. 2002;96(Suppl A):S9–15. doi: 10.1016/S0954-6111(02)90077-6. - DOI - PubMed
    1. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH Publication number 02-3659. 2002. http://www.ginasthma.org updated 2004. Date last accessed: February 10 2005.
    1. British Thoracic Society and Scottish Intercollegiate Guidelines network. British guidelines on the management of asthma. 2004. http://www.sign.ac.uk Date last accessed:February 10 2005.
    1. Ram F, Cates C, Ducharme F. Long-acting β2 -agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;(1):CD003137. - PubMed
    1. Chapman ID, Foster A, Morley J. The relationship between inflammation and hyperreactivity of the airways in asthma. Clin Exp Allergy. 1993;23(3):168–171. doi: 10.1111/j.1365-2222.1993.tb00877.x. - DOI - PubMed

Publication types

MeSH terms